$443.89
Value $239B
AMGN and ELMD stock compared: price, dividend, valuation and results, from SEC filings.
$443.89
Value $239B
$23.40
Value $196M
Amgen (AMGN) has a market value of $239B and Electromed (ELMD) $196M. Over the last year, with dividends, AMGN moved +33.5% and ELMD -5.0%. The P/E is 25.5 for AMGN and 16.4 for ELMD. Dividend yield: AMGN 2.24%, ELMD none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
AMGN$239B
ELMD$196M
AMGN is 1,222 times ELMD
Revenue, 12 months
AMGN$38.9B
ELMD$76M
AMGN is 515 times ELMD
Net income, 12 months
AMGN$9.4B
ELMD$12M
AMGN is 787 times ELMD
Operating margin
AMGN32.4%
ELMD19.5%
12.9 points apart
ROIC
AMGN16.2%
ELMD23.5%
7.3 points apart
P/E
AMGN25.5
ELMD16.4
AMGN is 1.6 times ELMD
Dividend yield
AMGN2.2%
ELMD0.0%
2.2 points apart
5-year return
AMGN+149.9%
ELMD+98.0%
51.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
AMGN+149.9%
ELMD+98.0%
| Period | AMGNWith dividends | ELMDWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +33.5%Price +29.9% | -5.0%Price -5.0% |
| 3 years since November 17, 2023 | +81.6%+22.0% a yearPrice +67.3% | +122.9%+30.6% a yearPrice +122.9% |
| 5 years since November 17, 2021 | +149.9%+20.1% a yearPrice +115.7% | +98.0%+14.6% a yearPrice +98.0% |
| 10 years since November 21, 2016 | +307.9%+15.1% a yearPrice +205.0% | +420.0%+17.9% a yearPrice +420.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
AMGNAmgenELMDElectromed
| Price | $443.89 | $23.40 |
|---|---|---|
| Market value | $239B | $196M |
| Enterprise value (EV) | $280B | $180M |
| P/E | 25.5 | 16.4 |
| P/E, 5-year median | 23.0 | 29.8 |
| P/B | 16.7 | 3.7 |
| EV/EBIT | 22.2 | 12.2 |
| Free cash flow yield | 4.0% | 4.5% |
| Revenue, 12 months | $38.9B | $76M |
|---|---|---|
| Net income, 12 months | $9.4B | $12M |
| Free cash flow, 12 months | $9.6B | $8.7M |
| Earnings per share, 12 months | $17.25 | $1.38 |
| Revenue growth, year on year | 10.0% | 15.3% |
| Revenue growth a year, past | +7.6%over 5 years | +15.6%over 5 years |
| EPS growth a year, past | +2.9%over 5 years | +36.9%over 5 years |
| Gross margin | 70.9% | 79.0% |
|---|---|---|
| Operating margin | 32.4% | 19.5% |
| Net margin | 24.1% | 15.8% |
| ROIC | 16.2% | 23.5% |
| ROE | 87.8% | 24.3% |
| Cash | $13.2B | $16M |
|---|---|---|
| Total debt | $54.0B | $133.0K |
| Net debt / EBITDA | 2.3 | -1.0 |
| Interest cover | 4.8× | – |
| Dividend yield | 2.2% | – |
|---|---|---|
| Dividend per share, 12 months | $9.94 | – |
| Dividend growth a year, past | +8.1%over 5 years | – |
| Buyback yield | – | 2.0% |
| Shareholder yield | 2.2% | 2.0% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Amgen ($239B) is about 1,222.3 times Electromed ($196M), at today's prices.
Since November 21, 2016, AMGN's price moved +205.0% and ELMD's +420.0%. With dividends: AMGN +307.9% (+15.1% a year), ELMD +420.0% (+17.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.24% for Amgen and none for Electromed. Over the last twelve months they paid $9.94 and – per share.
At today's price, the P/E is 25.5 for AMGN and 16.4 for ELMD. The median of the last five years was 23.0 and 29.8, which shows where each stands against its own past.
Over the last twelve months, the net margin was 24.1% for Amgen and 15.8% for Electromed, and the operating margin 32.4% and 19.5%. Revenue was $38.9B and $76M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.